Clinical efficacy of dirithromycin in patients with bacteremic pneumonia

Hernández, Jesús M.; Sides, Gregory D.; Conforti, Paul M.; Smietana, M

doi:10.1016/s0149-2918(96)80067-1

Cited by 12 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The literature review for the period 1981–2008 provided only 19 acceptable articles relevant to the antibiotic management of CAP 277 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 . [Ib] [Ib] [Ib] [Ib] [II] [Ib] [Ib] [Ib] [Ib] [Ib] [Ib] [Ib] [Ib] [Ib] [Ib] [Ib] [Ib] [Ib] [Ib] The remainder were rejected for the following reasons: inadequately powered studies or a retrospective design,102 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 non-blinded/non-randomised studies,274 401 402 403 404 405 antibiotic not available in the UK or withdrawn,357 361 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 study population or management unrepresentative of normal clinical practice in the UK,377 442 …”

Section: Section 8 Antibiotic Managementmentioning

confidence: 99%

BTS guidelines for the management of community acquired pneumonia in adults: update 2009

Lim

Baudouin²,

George³

et al. 2009

Thorax

1,163

1,073

View full text Add to dashboard Cite

Section: Section 8 Antibiotic Managementmentioning

confidence: 99%

BTS guidelines for the management of community acquired pneumonia in adults: update 2009

Lim

Baudouin²,

George³

et al. 2009

Thorax

1,163

1,073

View full text Add to dashboard Cite

“…It is reassuring that both the rates of clinical and bacteriologic success achieved by telithromycin in these patients (90.2 and 93.9%, respectively) were similar to those in the overall population, and consistent with outcomes reported for other antibacterials. 51,52 In conclusion, telithromycin 800 mg once daily for 5, 7, or 7 -10 days provides good coverage against key respiratory tract pathogens, including those resistant to penicillin and/or macrolides.…”

Section: Discussionmentioning

confidence: 96%

Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections

Low

Felmingham

Brown³

et al. 2004

Journal of Infection

View full text Add to dashboard Cite

“…All isolates in this study were susceptible to erythromycin. 46 It should be noted that the present analysis is not a prospective study and does not fulfill the criteria of a formal meta-analysis. However, the similar, standardized design of the eight studies supports the pooling of data obtained from the relatively small number of bacteremia cases identified across these studies.…”

Section: Article In Pressmentioning

confidence: 95%

“…44 In studies of the fluoroquinolone levofloxacin, 90.7% (98/108) of patients with pneumococcal bacteremia had a successful clinical response, including 91.7% (11/12) of patients infected with a macrolide-or penicillin-resistant strain. 45 Similarly, in studies to evaluate the efficacy and safety of dirithromycin in the treatment of acute bacteremic pneumonia, 46 a favorable clinical response post-therapy was observed in 90.9% (10/11) and 100% (8/8) of pneumococcal bacteremic patients treated with dirithromycin and erythromycin, respectively. All isolates in this study were susceptible to erythromycin.…”

Section: Article In Pressmentioning

confidence: 99%

Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia

Carbon

Rensburg

Hagberg

et al. 2006

Respiratory Medicine

View full text Add to dashboard Cite

This retrospective analysis was performed to determine the clinical and bacteriologic efficacy of the ketolide antibacterial telithromycin in patients with community-acquired pneumonia (CAP) with pneumococcal bacteremia. Patients 13 years old with radiologically confirmed CAP and a positive blood culture for Streptococcus pneumoniae at screening were analyzed from eight multicenter Phase III/IV clinical trials. In four open-label, non-comparative studies, patients received telithromycin 800 mg once daily for 7-10 days. In four randomized, controlled, double-blind, comparative studies, patients received telithromycin 800 mg once daily for 5-10 days or a comparator antimicrobial (amoxicillin 1000 mg three times daily, clarithromycin 500 mg twice daily, or trovafloxacin 200 mg once daily) for 7-10 days. In total, 118 patients (telithromycin, 94/1061 [8.9%]; comparator, 24/244 [9.8%]) had documented pneumococcal bacteremia. Those who were treated with telithromycin achieved a clinical cure rate of 90.2% (74/82, per-protocol population); S. pneumoniae was eradicated in 77/82 (93.9%) bacteremic patients who received telithromycin and 15/19 (78.9%) comparator-treated patients. Clinical cure was also observed among telithromycin-treated bacteremic patients who were infected with penicillin- or erythromycin-resistant strains of S. pneumoniae (5/7 and 8/10, respectively). In conclusion, telithromycin achieves high clinical and bacteriologic cure rates in CAP patients with pneumococcal bacteremia.

show abstract

Clinical efficacy of dirithromycin in patients with bacteremic pneumonia

Cited by 12 publications

References 28 publications

BTS guidelines for the management of community acquired pneumonia in adults: update 2009

BTS guidelines for the management of community acquired pneumonia in adults: update 2009

Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections

Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia

Contact Info

Product

Resources

About